Nevras Vasileios, Milaras Nikias, Katsioulis Christos, Sotiriou Zoi, Tsalamandris Sotirios, Gkounti Georgia, Skevos Sideris
Cardiology Department, General Hospital of Thessaloniki G.Gennimatas, Thessaloniki, Thessaloniki, Greece.
Cardiology Department, General Hospital of Athens Hippokration, Athens, Athens, Greece.
Curr Probl Cardiol. 2023 Mar;48(3):101503. doi: 10.1016/j.cpcardiol.2022.101503. Epub 2022 Nov 17.
Antiphospholipid syndrome(APS) is an autoimmune disorder characterized clinically by vascular thrombosis and/or pregnancy morbidity, associated with persistently elevated titers of antiphospholipid antibodies on at least two measurements over 12 weeks apart. In this study, we conducted a systematic review of the literature utilizing the Pubmed platform, in order to acquire clinical information about acute coronary syndromes in patients with APS. The obtained articles were reviewed in order to register the clinical characteristics, the rate of occurrence, the prognosis and the therapeutic approach of these patients. APS should be considered in young patients with acute myocardial infarction, even in patients with normal coronary arteries. The pharmaceutical approach is mainly based on the vitamin K antagonists, and in certain occasions aspirin, without any definite guidelines on the subject. Further randomized clinical trials are imperative for a better understanding of the particular characteristics of this group of patients, so that a more complete therapeutic approach to be obtained.
抗磷脂综合征(APS)是一种自身免疫性疾病,临床特征为血管血栓形成和/或妊娠并发症,与在至少相隔12周的两次测量中抗磷脂抗体滴度持续升高相关。在本研究中,我们利用PubMed平台对文献进行了系统回顾,以获取有关APS患者急性冠状动脉综合征的临床信息。对获取的文章进行了综述,以记录这些患者的临床特征、发生率、预后和治疗方法。对于急性心肌梗死的年轻患者,即使冠状动脉正常,也应考虑APS。药物治疗主要基于维生素K拮抗剂,在某些情况下使用阿司匹林,但在该主题上没有任何明确的指南。进一步的随机临床试验对于更好地了解这组患者的特殊特征至关重要,以便获得更完整的治疗方法。